Climb Bio, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CLYM Nasdaq 2834 climbbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Climb Bio, Inc.

Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference - Nov 2nd, 2026 5:00 am
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026 - Oct 24th, 2026 5:30 pm
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 - Oct 23rd, 2026 2:01 pm
Deutsche Bank starts Climb Bio at Buy, citing compelling autoimmune pipeline - Oct 20th, 2026 9:14 am
Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year? - Oct 20th, 2026 6:40 am
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug - Oct 2nd, 2026 7:30 am
Raymond James Updates Healthcare Top Picks for October - Oct 1st, 2026 2:26 pm
The Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' Data - Sep 23rd, 2026 2:12 pm
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal - Sep 4th, 2026 3:00 am
Why Climb Bio, Up 1,300% Over 17 Months, Just Took A Tumble - Sep 3rd, 2026 2:51 pm
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug - Sep 3rd, 2026 12:02 pm
Climb Bio Shares Rise 17% After Phase 1 CLYM116 Trial Data - Sep 3rd, 2026 7:37 am
Climb Bio to Present at Upcoming Investor Conferences - Sep 2nd, 2026 5:00 am
Climb Bio (CLYM) Advances Phase 2 Trial In China, Is The Valuation Already Priced In? - Aug 26th, 2026 12:18 am
Do Climb Bio’s (CLYM) Mixed Loss Trends Reveal a Shifting Path to Sustainable Scale? - Aug 18th, 2026 1:09 am
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates - Aug 6th, 2026 5:00 am
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year? - Jul 8th, 2026 7:40 am
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026 - Jun 11th, 2026 5:00 am
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development - Jun 5th, 2026 5:00 am